Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Adagene Has Received Written Feedback From The FDA On Its Clinical Development Plan To Evaluate Muzastotug (ADG126) In Combination With Merck's Keytruda For Microsatellite Stable Colorectal Cancer, Patients Enrollment In Phase 2 To Start In 2H 2025

Author: Benzinga Newsdesk | July 15, 2025 06:08am

Posted In: ADAG